gisadenafil
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00163098)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
Phosphodiesterase 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1- Mol. weight
- 519.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1928262 ↗
Also known as
- 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2h-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine
- 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2h-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine benzenesulphonate
- gisadenafil
- gisadenafil
- gisadenafil
- uk369003
- uk 369003
- uk 369,003
- uk-369003
- uk-369003
- uk-369003
- uk-369,003
- uk-369,003
- uk-369,003
- uk369,003
- uk369,003
- uk369,003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00814736 | Phase 1 | Aug 1, 2008 | Pfizer |
| NCT00479505 | Phase 2 | Jun 1, 2007 | Pfizer |
| NCT00457457 | Phase 2 | May 1, 2007 | Pfizer |
| NCT00408954 | Phase 2 | Mar 1, 2007 | Pfizer |
| NCT00141349 | Phase 2 | Feb 1, 2005 | Pfizer |
| NCT00174486 | Phase 2 | Feb 1, 2005 | Pfizer |
| NCT00163098 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2004 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 7 | 7 | 2 | 2004 |
1 organizations
Page 1 / 1